摘要
本研究采用实时荧光定量PCR法,对保定传染病医院332例临床样本的测定以及临床数据的分析,发现HBV-DNA与HBV-pgRNA、HBV-LP以及HBV-pgRNA与HBV-LP具有相关性(r=0.7152,P<0.0001;r=0.3780,P<0.0001;r=0.3367,P<0.0001);按照HBeAg状态进行分析,当乙型肝炎病毒感染患者的HBeAg呈阳性时,其血清HBV-DNA以及HBV-pgRNA的平均含量均处于较高水平,而血清HBV-LP的含量相对较低,且血清HBV-pgRNA与HBsAg具有相关性;当乙型肝炎病毒感染患者的HBeAg呈阴性时,HBV-pgRNA的平均含量与HBV-DNA的平均含量接近,但其检出率高于HBV-DNA的检出率,而血清HBV-pgRNA与HBsAg的相关性较弱;血清HBcAb与HBV-pgRNA具有相对较弱的相关性。
Objective The aim of this study was to investigate the correlation between pregenomic RNA(pgRNA)and different serological indexes of Hepatitis B Virus(HBV)in chronic hepatitis B(CHB)patients.Methods The clinical samples of 332 CHB patients were collected from Baoding Hospital of Infectious Diseases.Real-time fluorescence quantitative PCR method was used to measure the copy numbers of HBV pgRNA.The correlation between pgRNA levels and serological indexes of HBV and some other clinical data were analyzed.Results It was found that the HBV-DNA viral load was correlated with the levels of HBV-pgRNA and HBV-large surface protein(HBV-LP)(r=0.7152 and 0.3780,respectively,P<0.0001).The HBV-pgRNA level were correlated with HBV-LP(R=0.3367,P<0.0001).In HBeAg positive patients,the average copy numbers of serum HBV-DNA and HBV-pgRNA were at higher levels,whereas the quantitative levels of serum HBV-LP were relatively low,and the serum HBV-pgRNA load was correlated with HBsAg level.In HBeAg negative patients,the average copy numbers of HBV-pgRNA were close to that of HBV-DNA,but the detection rate of pgRNA was higher than that of HBV-DNA.A weaker correlation was found between the serum HBV-pgRNA and HBsAg in the HBeAg negative patients,and between serum HBcAb and HBV-pgRNA.Conclusion Quantitative detection of serum HBV-pgRNA level can serve as an auxiliary detected parameter as other serological markers to provide guidance for safely withdrawal of anti-HBV drugs.
作者
张明跃
曹明
王凯翔
陈浩
ZHANG Ming-yue;CAO Ming;WANG Kai-xiang;CHEN Jie(Molecular Biology Laboratory,Baoding People′s Hospital,Hebei 071000,China)
出处
《肝脏》
2021年第7期747-749,共3页
Chinese Hepatology
基金
艾滋病和病毒性肝炎等重大传染病防治专项课题(2017ZX10302201)。